抗血管生成化疗降低鼠肉瘤组织微血管密度及血清VEGF浓度

目的：研究环磷酰胺（CTX）抗血管生成化疗对昆明鼠皮下肉瘤组织微血管密度及血清血管内皮细胞生长因子（VEGF）浓度的影响及机理。方法：将荷S180肉瘤（100mm^3）鼠随机分成A组（CTX抗血管生成化疗组），B组（CTX标准化疗组）和生理盐水对照组（C组），按实验方案处理后，检测抑瘤率和肿瘤组织内微血管密度，检测不同时段血清VEGF浓度。结果：A组和B组抑瘤率分别为88．7％和90．6％，A、B及C组微血管密度分别为（7．6±5．2）个／mm^2、（16．5±5．5）个／mm^2及（17．9±4．7）个／mm^2，A、B及C组d21时血清VEGF浓度分别为（21．23±7．57）pg／ml、（41．01±14．37）pg／ml及（35．24±13．87）pg／ml。结论：抗血管生成化疗持续降低外周血VEGF值，降低肿瘤组织内的微血管密度，直接降低VEGF浓度是抗血管生成化疗的一个重要机制。

Anti -angiogenesis chemotherapy decrease murine sarcoma MVD and VEGF serum level

Objective：To observe the effect and mechanism of cyclophosphamide （CTX） anti - angiogenesis chemotherapy（ACT） on the microvessel density （MVD） and vascular endothelia growth factor（VEGF） serum level in murine subcutaneous sarcoma caused by S180 cells. Methods： Mice with the sarcoma S180 were randomly divided into 3 groups ： A, ACT group ; B, standard CTX chemotherapy group ; C, saline control group. After administration, the MVD of the sarcoma was measured by immunohistochemical method, the VEGF serum levels were measured by ELISA method at four different time points, and the mean tumor inhibition rates were calculated. Results： The mean tumor inhibition rates were 88.7% and 90.6% in group A and B, respectively. Immunohistochemical results showed that the MVD in group A,B and C were（7.6 ±5.2）/mm^2, （16.5 ±5.5） /mm^2 and（17.9 ±4.7）/mm^2 ,respectively. And the VEGF serum levels at the 21 ^st day after administration in group A, B and C were（21.23 ± 7.57） pg/ml, （41.01 ± 14.37 ） pg/ml and （ 3 5.2 4 ± 13.87 ） pg/ml, respectively . Conclusion： CTX anti - angiogenesis chemotherapy can decrease mouse VEGF serum level persistently, decrease the MVD of sarcoma. Directly down regulation VEGF poten- tially is a key mechanism of the ACT.